EyePoint Pharmaceuticals, Inc., a Massachusetts-based biopharmaceutical company, has reached a settlement with the United States government, agreeing to pay $4,657,463.18 to resolve allegations that it violated the False Claims Act. The settlement addresses claims that EyePoint engaged in a sophisticated kickback scheme designed to induce Ambulatory Service Centers (ASCs) to purchase and dispense DEXYCU, a physician-administered injectable drug used to treat ocular inflammation following cataract surgery. The alleged misconduct took place over a four-year period, beginning with the drug’s commercial launch on January 1, 2019, and continuing through March 1, 2023.
According to the Department of Justice (DOJ), the settlement also includes an additional $21,518.68 to be paid to several participating states whose Medicaid programs were affected by the alleged fraudulent billing. Beyond the financial penalties, EyePoint has entered into a rigorous five-year Corporate Integrity Agreement (CIA) with the Department of Health and Human Services Office of Inspector General (HHS-OIG), which will require the company to implement significant compliance reforms and undergo regular external monitoring.
The Mechanics of the Alleged Kickback Scheme
The core of the government’s allegations involves two primary methods EyePoint used to manipulate the market for DEXYCU: the implementation of an "Assurance Program" and the distribution of excessive free samples. Under the federal Anti-Kickback Statute, pharmaceutical companies are prohibited from offering or paying any remuneration to induce the purchase or recommendation of items or services covered by federal healthcare programs, such as Medicare and Medicaid.
The "Assurance Program" was characterized by the government as a financial safety net for healthcare providers. EyePoint allegedly promised to reimburse or compensate ASCs if health insurers denied a claim for DEXYCU or if the insurance reimbursement fell below the ASC’s actual purchase cost. In the highly regulated world of federal healthcare, such "money-back guarantees" are viewed as illegal inducements because they eliminate the financial risk for the provider, thereby encouraging the use of a specific drug based on financial gain rather than clinical necessity.
Furthermore, the United States alleged that EyePoint provided ASCs with an excessive volume of free samples of DEXYCU. While the distribution of limited samples for patient trial is generally permitted, the government contended that EyePoint’s distribution was so vast that it functioned as a form of "price-leveling" or a "kickback in kind." By providing a high volume of free units, the company effectively lowered the net cost of the drug for the ASCs, creating a financial incentive for the facilities to choose DEXYCU over competing treatments.
Contextual Background: DEXYCU and the Cataract Surgery Market
To understand the impact of these allegations, it is necessary to examine the specific medical and economic context of DEXYCU. Approved by the FDA in early 2018, DEXYCU is a long-acting corticosteroid. Unlike traditional post-operative treatments that require patients to self-administer eye drops multiple times a day—a process often fraught with compliance issues—DEXYCU is injected by the surgeon directly into the eye at the conclusion of cataract surgery.
Cataract surgery is one of the most frequently performed medical procedures in the United States, particularly among the elderly population. Because the vast majority of these patients are enrolled in Medicare, the financial stakes for drugs used in these procedures are immense. DEXYCU was marketed as a premium, physician-administered product. Under Medicare Part B, physicians and ASCs typically purchase such drugs and then bill Medicare for the cost plus a small percentage. When a manufacturer guarantees that the provider will never lose money on a drug—or provides enough free samples to inflate the provider’s profit margin—it corrupts the economic structure of the Part B program.
Chronology of the Case and the Whistleblower’s Role
The legal proceedings began not with a government audit, but with a "qui tam" or whistleblower lawsuit. The case, captioned U.S. ex rel. AFCE LLC, et al., v. EyePoint Pharmaceuticals, Inc., was filed in the District of Massachusetts. Under the False Claims Act, private individuals or entities (relators) with knowledge of fraud against the government can file a lawsuit on behalf of the United States.
- January 2019: EyePoint officially launches DEXYCU in the U.S. market and allegedly begins the Assurance Program and the aggressive sampling strategy.
- 2021: The whistleblower, AFCE LLC, files a confidential complaint under seal, alerting the Department of Justice to the alleged kickback practices.
- 2021–2023: Federal investigators from the FBI and HHS-OIG, in coordination with the DOJ’s Civil Division, conduct an extensive investigation into EyePoint’s marketing and sales records.
- March 2023: The period of alleged misconduct concludes.
- 2024: The parties reach a settlement agreement. As part of the resolution, the whistleblower, AFCE LLC, will receive a "relator’s share" of $791,768.74 from the federal recovery, as incentivized by the False Claims Act.
Official Statements and Government Response
The settlement was announced as part of a broader, ongoing effort by the Biden-Harris Administration to crack down on healthcare fraud and rising drug prices. Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division emphasized the danger of such schemes, stating, "Kickbacks by pharmaceutical companies increase the cost of drugs used by patients and paid for by federal health care programs. The Civil Division will hold accountable anyone who pays unlawful kickbacks."
Leah B., the United States Attorney for the District of Massachusetts, echoed these sentiments, noting that such financial incentives can cloud medical judgment. "Through these efforts, we protect patients by removing providers’ financial incentives to prescribe or dispense products that may not be medically necessary for the patient and protect the public from fraud, waste, and abuse," she said.
Acting Deputy Inspector General for Investigations Scott J. Lampert of the HHS-OIG highlighted the betrayal of trust inherent in these cases. "Pharmaceutical companies that attempt to boost profits through unlawful kickbacks undermine the integrity of federal health care programs and betray the patients who rely on them," Lampert remarked. He added that the HHS-OIG would continue to "aggressively pursue any entity that seeks to corrupt medical decision making."
The Corporate Integrity Agreement: A Five-Year Oversight
A critical component of this resolution is the five-year Corporate Integrity Agreement (CIA) EyePoint entered into with the HHS-OIG. A CIA is a standard tool used by the government to ensure that a company does not revert to fraudulent practices after a settlement.
Under this agreement, EyePoint is required to:
- Establish a Compliance Committee: Appoint a compliance officer and a committee to oversee the company’s adherence to federal healthcare laws.
- Implement Training Programs: Mandate comprehensive compliance training for all employees and executives, particularly those involved in sales and marketing.
- Engage an Independent Review Organization (IRO): Hire a third-party auditor to conduct annual reviews of the company’s systems, transactions, and practices to ensure they meet the requirements of the Anti-Kickback Statute.
- Reporting Obligations: Regularly report to the HHS-OIG regarding its compliance efforts and disclose any "reportable events," such as potential violations of law.
Failure to comply with the terms of the CIA can lead to significant stipulated penalties or even exclusion from participating in Medicare and Medicaid—a "death penalty" for most pharmaceutical companies.
Broader Impact and Industry Analysis
The EyePoint settlement serves as a stark warning to the pharmaceutical and medical device industries regarding "value-added" programs and physician-support initiatives. While companies often frame "Assurance Programs" as a way to assist patients in accessing medication, the DOJ’s stance remains clear: if a program shifts the financial risk away from the provider in a way that induces sales, it is likely an illegal kickback.
This case also underscores the increasing reliance of the federal government on the False Claims Act as a primary tool for market regulation. In the last decade, the DOJ has recovered billions of dollars through FCA litigation, much of it initiated by whistleblowers. The involvement of the newly launched "Task Force to Eliminate Fraud" and the "National Fraud Enforcement Division" indicates that the administration is dedicating more resources to identifying and prosecuting sophisticated financial schemes in the healthcare sector.
For the healthcare industry, the implications are twofold. First, pharmaceutical companies must scrutinize their marketing programs—especially those involving samples and financial guarantees—to ensure they do not run afoul of the Anti-Kickback Statute. Second, Ambulatory Service Centers and other providers must be wary of accepting "assistance" from manufacturers that seems "too good to be true," as they too can be held liable for participating in kickback schemes.
As the government continues to battle rising healthcare costs, the scrutiny of physician-administered drugs and the relationships between manufacturers and providers is expected to intensify. The resolution of the EyePoint matter demonstrates that even relatively smaller settlements (in the $4-5 million range) are pursued with the full weight of federal investigative agencies to maintain the integrity of the American healthcare system.
